Neuralstem, Inc. (CUR): Jones Jonathan Brian Lloyd , CFO of Neuralstem, Inc. purchased 31,250 shares on Sep 23, 2016. The Insider buying transaction was reported by the company on Sep 26, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.32 per share for a total value of $10,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 26, 2016, Richard J Daly (CEO) purchased 31,250 shares at $0.32 per share price.On Nov 16, 2015, Karl Johe (Chief Scientific Officer) sold 25,000 shares at $1.09 per share price.
Neuralstem (CUR) witnessed a volatile trading activity on Thursday Sep 22, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $0.31 and reached the intraday high at $0.321. The bulls started the profit booking and pushed the shares to intraday low of $0.3. The trading session was marked by a volume range of 8,67,793 shares exchanging hands. The 52-week high of the shares is $1.96 and the 52-week low is $0.19. The market cap of the company stands at $36 M and there are 11,47,60,960 shares in public circulation.
Company has been under the radar of several Street Analysts.Neuralstem is Initiated by ROTH Capital to Buy and the brokerage firm has set the Price Target at $1.20. The Rating was issued on Aug 29, 2016.
Neuralstem Inc. (Neuralstem) is engaged in development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and its small molecule compounds. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from all areas of the developing human brain and spinal cord thus enabling the generation of physiologically relevant human neurons of all types. It has developed and patented a series of small molecule compounds. The Company is developing products using technology including Cell Therapy and Small Molecule Pharmaceutical Compounds. The Company has a wholly owned subsidiary Suzhou Sun-Now Biopharmaceutical Co. Ltd. in China. Its clinical programs include the NSI-566 and NSI-189.